The phase III clinical trial CAUREL comparing the effects of durvalumab combined with osimertinib with osimertinib alone in T790M-positive NSCLC patients who have been treated with EGFR TKIs and found that the incidence of EGFR TKI-associated interstitial pneumonitis in both EGFR TKI and nivolumab cohort was much higher than TKI single drug cohort (95). Here, EGFR is linked to non-small cell lung carcinoma.